Stocks Health care IPHA

NASDAQ · Health care

Innate Pharma SA (IPHA)

Innate Pharma SA reported revenue of €9M in fiscal 2025, down 55.2% from a year earlier. It posted a net loss of €49.2M. In fiscal 2025 capital spending exceeded operating cash flow by €52.9M. At December 31, 2025 it held €28.1M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 1, 2026.

Watch IPHA in 60 seconds

What Innate Pharma SA does

Innate Pharma SA is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IPHA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Innate Pharma SA has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 17, 2026
   Foreign issuer update 6-K
2. September 17, 2026
   Foreign issuer update 6-K
3. September 17, 2026
   Foreign issuer update 6-K
4. September 10, 2026
   Foreign issuer update 6-K
5. September 2, 2026
   Foreign issuer update 6-K
6. August 19, 2026
   Foreign issuer update 6-K
7. August 14, 2026
   Foreign issuer update 6-K
8. August 10, 2026
   Foreign issuer update 6-K
9. July 23, 2026
   Foreign issuer update 6-K
10. July 21, 2026
    Foreign issuer update 6-K

Insider trades

What the people running Innate Pharma SA did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IPHA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IPHA

What does Innate Pharma SA do?

Innate Pharma SA is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IPHA.

Is Innate Pharma SA profitable?

No. In fiscal 2025 it reported a net loss of €49.2M on revenue of €9M.

How much revenue does Innate Pharma SA make?

In fiscal 2025 Innate Pharma SA reported revenue of €9M. That is 55.2% less than a year earlier.

When did Innate Pharma SA last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 1, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 17, 2026.

Similar companies

Compare IPHA with

Compare IPHA with any company

Follow IPHA

Get an email when Innate Pharma SA files with the SEC: results, executive changes, material agreements and annual reports.

Follow IPHA: get an email when it files

Where the numbers come from

Financial figures are the values Innate Pharma SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.